1 / 49

α -Synuclein Interaction with Phospholipids: Possible Implications for Parkinson’s Disease

α -Synuclein Interaction with Phospholipids: Possible Implications for Parkinson’s Disease. Literature Seminar by Jessica L. Anderson. Outline. Parkinson’s Disease (PD) α -Synuclein involvement in PD Class A 2 α -helical model Defective interaction of mutant α -synuclein

studs
Download Presentation

α -Synuclein Interaction with Phospholipids: Possible Implications for Parkinson’s Disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. α-Synuclein Interaction with Phospholipids:Possible Implications for Parkinson’s Disease Literature Seminar by Jessica L. Anderson

  2. Outline • Parkinson’s Disease (PD) • α-Synuclein involvement in PD • Class A2α-helical model • Defective interaction of mutant α-synuclein • Inhibition of phospholipase D2 (PLD2) • α-Synuclein role in dopamine homeostasis • Model for PD pathogenesis

  3. Parkinson’s Disease • Affects 1-1.5 million Americans • Symptoms • Bradykinesia (Slowness of movement) • Rigidity • Tremor • Problems Walking • Poor Balance • Caused by loss of dopamine in the nigrostriatal pathway

  4. Nigrostriatal Pathway http://www.aafp.org/afp/990415ap/2155.html (8/28/02)

  5. medweb.bham.ac.uk(8/28/02) Normal vs. Diseased Brains

  6. Outline • Parkinson’s Disease (PD) • α-Synuclein involvement in PD • Class A2α-helical model • Defective interaction of mutant α-synuclein • Inhibition of phospholipase D2 (PLD2) • α-Synuclein role in dopamine homeostasis • Model for PD pathogenesis

  7. Lewy Bodies www.saigata-nh.go.jp/ (8/28/02)

  8. www.sfn.org/images/brainbriefings/ august2001_big.jpg (8/28/02) Lewy Bodies Stain Positive for α-Synuclein

  9. α-Synuclein • 14-kD protein with “random coil” secondary structure • Localized to presynaptic vesicles • Function of protein remains unknown • Up to 1% of total protein from soluble brain fractions • Two other family members, b- and g-synuclein

  10. α-Synuclein Function • Under oxidative stress • Non-dopaminergic cell  Neuroprotective • Dopaminergic cell  Neurotoxic • Potent in vivo inhibitor of phospholipase D2 • Regulates the size of the synaptic vesicle pool

  11. α-Synuclein Fibrillization Volles et al. Biochemistry 2001

  12. Mutant α-Synuclein • Two disease causing mutations exist • A30P • A53T • Lead to early onset PD • Form fibrils faster (A53T) or at about the same rate (A30P) as wild type • Form fibrils at lower protein concentration than wild type

  13. A30P A53T Amphipathicdomain NAC domain Acidic Tail pKTKEGVaxaA repeats Regions of α-Synuclein

  14. Outline • Parkinson’s Disease (PD) • α-Synuclein involvement in PD • Class A2α-helical model • Defective interaction of mutant α-synuclein • Inhibition of phospholipase D2 (PLD2) • α-Synuclein role in dopamine homeostasis • Model for PD pathogenesis

  15. Ile,Leu, Phe Lys, Arg Glu, Asp Class A2α-Helical Model • 11 or 22-mer tandem repeats • Clustering of Lys at polar/nonpolar face • Clustering of Glu on polar face • High Lys:Arg ratio • Lysine “snorkeling” Segrest et al. J. Lipid Res. 1992

  16. Phospholipid Protein α-Synuclein Preferentially Binds Brain Phospholipids α-Synuclein Ovalbumin Brain phospholipid extract POPC vesicles Davidson et al.J. Biol. Chem. 273 (16) 1998

  17. Lipid Head Group Structure Phosphatidylcholine (PC) Phosphatidylethanolamine (PE) Phosphatidic Acid (PA) Phosphatidylserine (PS) Phosphatidylinositol (PI) www.lipid.co.uk (9/04/02)

  18. α-Synuclein Selectively Binds Acidic Phospholipids Davidson et al.J. Biol. Chem. 273 (16) 1998

  19. Lipid Binding Causes Conformation Change Free Protein PC PC/PA PC/PS Davidson et al.J. Biol. Chem. 273 (16) 1998

  20. Helical Wheel Analysis of α-Synuclein Hydrophobic Polar Charged * = Helix Breaker Davidson et al.J. Biol. Chem. 273 (16) 1998

  21. Conclusions • α-Synuclein binds phospholipid vesicles with a net negative charge • Lipid binding increases α-helical character

  22. Full Length Exon Deletion Abolishes Binding to PS; PA Binding is Unaffected Perrin et al. J.Biol.Chem. 275(44) 2000

  23. Single Exons Sufficient for Binding to PA Vesicles Full Length Perrin et al. J.Biol.Chem. 275(44) 2000

  24. Charged Residues on Hydrophobic Face Alter Phospholipid Binding Perrin et al. J.Biol.Chem. 275(44) 2000

  25. Biotinylation of Lysine and A30P Mutation Decrease Lipid Binding * = Biotinylation Perrin et al. J.Biol.Chem. 275(44) 2000

  26. α-Synuclein Bound to PS is Less α-helical POPC/POPA POPC/POPS Free Protein A30P WT A53T Perrin et.al. J.Biol.Chem. 275(44) 2000

  27. Conclusions • Entire hydrophobic region necessary for PS binding • Electrostatics not primary mediator of lipid binding • Lysine residues play a role in lipid binding

  28. Outline • Parkinson’s Disease (PD) • α-Synuclein involvement in PD • Class A2α-helical model • Defective interaction of mutant α-synuclein • Inhibition of phospholipase D2 (PLD2) • α-Synuclein role in dopamine homeostasis • Model for PD pathogenesis

  29. PC/PS PC/PA PE/PS PE/PA ----- Free protein ----- Free protein A30P Mutant Shows Defective Lipid Binding -θ 222 nm PS Binding PA Binding Jo et al. J. Mol. Biol. 315, 2002

  30. A30P POPS Binding Abolished at High Ionic Strength WT A30P -θ 222 nm Jo et al. J. Mol. Biol. 315, 2002

  31. pellet supernatant WT A30P Membrane Bound α-Synuclein is Dimeric α-syn ~ 14 kD Jo et al. J. Mol. Biol. 315, 2002

  32. Conclusions • A30P binds acidic vesicles less than wild type • Binding improves with PE vs. PC • Membrane bound α-synuclein is a dimer

  33. Outline • Parkinson’s Disease (PD) • α-Synuclein involvement in PD • Class A2α-helical model • Defective interaction of mutant α-synuclein • Inhibition of phospholipase D2 (PLD2) • α-Synuclein role in dopamine homeostasis • Model for PD pathogenesis

  34. Phospholipase D2 • Hydrolyzes PC to PA and choline • Localized to plasma membrane and possibly early endosomes • Involved in vesicle recycling • Constituitively active in vitro but constantly under (-) regulation in vivo

  35. Regulation of Vesicle Budding Liscovitch et al. Biochem J. 345, 2000

  36. α-Synuclein Inhibits Phospholipase D2 α β PLD1 PLD2 Jenco et al. Biochem. 37 (14), 1998

  37. PIP2 Cannot Overcome α-Synuclein Inhibition of PLD2 PIP2 [μM] Jenco et al. Biochem. 37 (14), 1998

  38. Lipid Concentration Affects Inhibition of PLD2 by α-Synuclein No Synuclein 100 nM α-synuclein Jenco et al. Biochem. 37 (14), 1998

  39. Conclusions • α- and β-Synucleins are inhibitors of PLD2 • Inhibition is selective for PLD2 • Inhibition is independent of PIP2 • Lipid concentration can reduce α-synuclein inhibition

  40. Outline • Parkinson’s Disease (PD) • α-Synuclein involvement in PD • Class A2α-helical model • Defective interaction of mutant α-synuclein • Inhibition of phospholipase D2 (PLD2) • α-Synuclein role in dopamine homeostasis • Model for PD pathogenesis

  41. Model of Dopamine Homeostasis Dopamine Neuron Dopamine Transporter VMAT2

  42. Decreased DAT and VMAT in LV-A53T Cells Lotharius et al. J. Biol. Chem. In Press

  43. A53T Cells Show Decreased Dopamine Uptake and Release GFP A53T Lotharius et al. J. Biol. Chem. In Press

  44. Dopamine Redistributed to Cytosol in A53T Cells Lotharius et al. J. Biol. Chem. In Press

  45. Conclusions • A53T α-synuclein expression in MESC2.10 cells • Reduces the number of synaptic vesicles • Redistributes dopamine from synaptic vesicles to the cytosol

  46. Outline • Parkinson’s Disease (PD) • α-Synuclein involvement in PD • Class A2α-helical model • Defective interaction of mutant α-synuclein • Inhibition of phospholipase D2 (PLD2) • α-Synuclein role in dopamine homeostasis • Model for PD pathogenesis

  47. Model for PD Pathogenesis Dopamine Dopamine Transporter VMAT2

  48. Protofibrillar a-synuclein Model for PD Pathogenesis Dopamine Dopamine Transporter VMAT2

  49. Thank You • Hilary Frase • Kaisa Ejendal • Ney Diop • Erin Seeley • Christa Feasley • Bindu Varghese • Erina Vlashi

More Related